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Background
Although the general public perceives cannabis as one of the less harmful illicit drugs, the past
decades saw a surge in treatment demands for CUDs (UNODC, 2014). Cannabis nowadays is
the primary illicit drug of concern in drug treatment services across North America, Oceania
and Africa (UNODC, 2014). The low perceived harms of cannabis use are reflected in the small
number of studies investigating the neurocognitive processes underlying CUDs [e.g., only 3
published functional Magnetic Resonance Imaging (fMRI) studies in individuals with a diagnosed
CUD compared to controls, contrasting more than 1000 studies in individuals with an Alcohol
Use Disorder]. Most studies on the mechanisms underlying cannabis abuse, including my own,
investigated heterogeneous groups of chronic or heavy cannabis users with various levels of
cannabis use related problems, not groups with diagnosed CUDs.
Even though a substantial part of regular cannabis users will not experience any clear negative
social and health consequences of cannabis, this does not imply that CUDs are less severe than other
Substance Use Disorders (SUDs). The mental health issues associated with CUDs are substantial
and often include comorbid psychiatric disorders including depression and anxiety (Stinson et al.,
2006). Moreover, CUDs are difficult to treat and long-term abstinence is achieved by fewer than
20% (Danovitch and Gorelick, 2012). This urgently calls for a better understanding of CUDs. It is
therefore time to reach out to those coping with CUDs by studying the mechanisms underneath.
The goal of this opinion article is twofold: First, I want to address the strong need for neurocognitive
studies in CUDs. Second, I propose that studying neurocognitive commonalities and differences
between CUDs and comorbid disorders like depression and anxiety has great potential to unravel
the mechanisms underlying CUDs and to eventually reveal new treatment targets.
Motivational and Control Processes in Cannabis Use Disorders
Strong motivations towards drug use (e.g., craving, automatic tendencies to attend to and approach
the drug), paired with an insufficient capacity to keep these under control are thought to play a
prominent role in SUDs (Goldstein and Volkow, 2002; Robinson and Berridge, 2003; Dawe and
Loxton, 2004; Everitt and Robbins, 2005; Wiers et al., 2007; Verdejo-Garcia and Bechara, 2009).
Recent behavioral studies suggest that this is also the case in CUDs: confrontation with cannabis
or related objects and contexts (i.e., cues) can trigger craving (e.g., Gray et al., 2011; Lundahl
and Johanson, 2011), capture their attention (attentional bias; e.g., Cousijn et al., 2013b; Asmaro
et al., 2014), and activate approach tendencies (approach bias; e.g., Field et al., 2006; Cousijn
et al., 2011). In addition, cognitive control-related functions like planning, organizing, problem
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solving, decision-making, and working-memory appear to be
impaired in individuals with a CUD (Fernandez-Serrano et al.,
2011). Chronic cannabis exposure may (temporarily) impair
cognitive control, but cognitive control deficits may also be a risk
factor for the onset of cannabis use and escalation into CUDs
(Cousijn et al., 2014).
Embracing Comorbidity as a Tool
While the comorbidity between CUDs and other psychiatric
disorders is widely accepted, neurocognitive studies mostly
study disorders in isolation. Comorbid symptoms are often
even controlled for by excluding such participants. A 3-year
longitudinal epidemiological study specifically investigated the
role of mental health factors in non-dependent versus dependent
heavy cannabis use (Van Der Pol et al., 2013). Although
externalizing psychiatric disorders like ADHD and conduct
disorder were common to non-dependent and dependent
users, internalizing psychiatric disorders such as mood and
anxiety disorders were uniquely associated with dependence.
Combined, the 283 almost daily cannabis users that participated
in my previous studies revealed a correlation of r =
0.50 between cannabis use-related problems and depression
symptoms (e.g., Cousijn et al., 2012; Beraha et al., 2013;
Cousijn et al., 2013a,b). Similarly as in SUDs, neurocognitive
models of depression (Weir et al., 2012) and anxiety disorders
(Bruhl et al., 2014) stress the importance of dyscontrol
over motivational processes and abnormal functioning of the
underlying brain systems in the emergence of these disorders.
Fronto-parietal and fronto-limbic brain networks are thought
to play a key role in this (Figure 1; Seeley et al., 2007).
The fronto-parietal network is thereby the main substrate
for relatively cold executive control (e.g., working memory,
attention, inhibition). The fronto-limbic network is primarily
involved in emotion regulation, salience attribution and the
integration of motivational information (e.g., reward, emotions)
into decision processes.
The overlap in neurocognitive mechanisms underlying SUDs
with depression and anxiety appears evident. Litle is known,
however, about why certain symptoms cluster together and
what differentiates disorders. From a clinical perspective, the
vague boudaries between psychiatric disorders, the heterogeneity
in psychiatric problems within patient groups and the poor
treatment response in a substatial number of patients also
underline the need to look beyond dichotomous disorder
classifications (Casey et al., 2013). The new edition of the
diagnostic statistical manual (DSM-V) introduced stages of
disorder severity but still relies on self-reports (American
Psychiatric Association, 2013). In the quest to identify more
objective biomarkers for psychiatric problems, the US National
Institute of Mental Health recently called for a transdiagnostic
dimensional approach in the study of psychiatric disorders,
in which the neurobiology underlying symptom dimensions is
central, not the disorder classification itself (Casey et al., 2013).
Embracing comorbid psychiatric problems, rather than factoring
them out in neurocognitive studies, is an important step in this
and I believe that such an approach has great potential to advance
FIGURE 1 | Fronto-parietal and fronto-limbic brain networks thought to
play an important role in cannabis use disorders, depression, and
anxiety disorders. preSMA, pre-supplementary motor cortex; dACC, dorsal
anterior cingulate gyrus; vACC, ventral anterior cingulate gyrus; OFC,
orbitofrontal cortex; S, striatum; A, amygdala; dPMC, dorsal premotor cortex;
DLPFC, dorsolateral prefrontal cortex; IFG, inferior frontal gyrus; AI, anterior
insula; PPC, posterior parietal cortex.
our knowledge of psychiatric disorders, including CUDs. An
additional advantage of such an approach is that participants with
comorbid problems are more representative of individuals with
(sub-threshold) psychiatric problems in the general population
and of patients in treatment.
Studying the common and unique neurocognitive
mechanisms underlying psychiatric disorders may help us
to identify new biomarker that could advance prevention and
treatment. In the case of CUDs, we can only speculate about
the neurocognitive mechanisms underlying CUDs, let alone
understand why depression and anxiety disorders are associated
with CUDs. Cognitive control deficits and malfunctioning of
the underlying fronto-parietal brain networks may be shared
between all three disorders, posing a general risk factor for the
development of CUDs, depression and anxiety disorders (Koob
and Volkow, 2010; Weir et al., 2012; Cousijn et al., 2013b; Bruhl
et al., 2014; Peterson et al., 2014). In contrast, motivational
processes within specific emotional and rewarding contexts may
differentiate disorders. Although abnormal approach-avoidance
behavior is common to all three disorders, depression and
anxiety are associated with overactive avoidance of certain
social and emotional situations (Trew, 2011; Caouette and
Guyer, 2014), whereas CUDs may be associated with overactive
approach of cannabis cues (Cousijn et al., 2011). Moreover, SUDs
including CUDs and depression are both characterized by low
positive affect (anhedonia) and abnormal reward responsiveness
within various fronto-limbic brain areas (Koob and Volkow,
2010; Hatzigiakoumis et al., 2011; Elman et al., 2013; Morgan
et al., 2013; Telzer et al., 2014). Interestingly, a recent PET
study among 14 heavy cannabis users showed a link between
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anhedonia and reduced dopamine transmission in the striatum
(Bloomfield et al., 2014). Unlike, CUDs, depression and anxiety
further show abnormal processing of social emotional stimuli
in the amygdala (Burghy et al., 2012; Weir et al., 2012; Caouette
and Guyer, 2014). Further, amygdala connectivity with the
ventral medial prefrontal cortex may differentiate between
anxiety and depression by uniquely contributing to certain
symptoms (Mcclure et al., 2007; Beesdo et al., 2009; Burghy et al.,
2012).
Genetics are also known to play an important role
in the risk for CUDs, depression and anxiety disorders.
Motivational and control processes are influenced by genetic
factors, including genes involved in drug metabolism and
neurotransmission (Sweitzer et al., 2012). Motivational and
control processes may thereby, at least partly, mediate the
genetic vulnerability to all three disorders. For example the
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism
affects dopamine binding in the striatum and is consistently
associated with SUDs, depression and anxiety disorders (gene-
disorder association indices retrieved from Gene Prospector;
Yu et al., 2008). The A1 allele of the DRD2 Taq1 A
polymorphism has been linked to reduced dopamine D2
receptor availability in the striatum, which could in turn
reduce general reward responsiveness (Belcher et al., 2014).
Another polymorphism consistently associated with all three
disorders is COMTval158met (Yu et al., 2008). The COMT
gene encodes an enzyme that is involved in the inactivation
of catecholamine neurotransmitters like dopamine, epinephrine,
and norepinephrine. The COMTval158met polymorphism has
been linked to altered dopamine signaling in the prefrontal
cortex, thereby influencing cognitive control (Bruder et al., 2005).
Important to note CUDs, depression and anxiety disorders
are polygenetic. Single genes are often only weakly associated
with the risk for certain psychiatric disorders. To investigate
genetic factors underlying polygenetic disorders large-scale
multicenter genome-wide studies are needed. To allow DNA
data contribution of small studies to large-scale consortia, DNA
data collection should be facilitated for new studies, even though
the primary objectives do not necessary comprise genetics.
Moreover, epigenetics should be considered, that is the processes
involved in long-term changes in gene expression that are
heritable to daughter cells. Interestingly, a recent study in mice
showed that a single epigenetic mechanisms (histonemethylation
of fosb) can influenced gene expression in the nucleus accumbens
and induce depression and addiction like behavior (Heller et al.,
2014).
A Critical Note
Although knowledge of the common and unique neurobiology
underlying comorbid disorders could identify biomarkers,
researchers and clinicians should carefully evaluate and compare
the clinical value of such measures for the individual patient.
Our group-based findings may not necessarily translate to
the individual. Also, neuroimaging techniques are expensive
compared to questionnaires and neuropsychological tests. It is
therefore important to explicitly test if certain neural indices
explain unique variance on top of simpler (and cheaper)
methods.
Conclusions
The worldwide high treatment demands for CUDs, but the
significant lack of studies investigating it warrant new studies
that investigate neurocognitive functions in cannabis users with
a clinically diagnosed CUDs. Uncovering the common and
unique neurocognitive mechanisms and associated (epi)genetics
underlying CUDs and highly comorbid disorders like depression
and anxiety can provide valuable knowledge for improving
current state-of-the-art treatments and for developing new
neuroscience based interventions, such as neurocognitive
training (e.g., approach-action retraining; Wiers et al., 2011),
neuromodulation (e.g., stimulating brain areas involved in
control; Ressler and Mayberg, 2007; Berlim et al., 2013; Da Silva
et al., 2013) and pharmacotherapy (e.g., medication that enhances
emotion regulation; Ressler and Mayberg, 2007; Sofuoglu, 2010;
Mohler, 2012; Farb and Ratner, 2014). I reiterate that it is vital to
studymotivational processes and cognitive control in ecologically
valid groups of individuals, that is, by including those coping with
comorbid psychiatric problems.
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